EVFM News and Press, Evofem Biosciences Inc. From 05/04/22

Evofem Biosciences press release (NASDAQ:EVFM): Q1 Revenue of $4.3M (+287.4% Y/Y). At March 31, 2022, the Company had $2.8 million in unrestricted cash and $4.2 million in restricted cash, as compared to $7.7 million of unrestricted cash and $5.1 million of restricted cash at Decemb...

Evofem Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update PR Newswire -- Double digit growth in net revenues over Q4 2021 -- -- Reduced selling and marketing costs 49% and total operating expense 19% vs. Q4 2021 -- ...

Evofem Improves Phexxi® Patient Experiences Through New Agreement with VitaCare Prescription Services PR Newswire Evofem Anticipates Greater Numbers of Phexxi® (lactic acid, citric acid, potassium bitartrate) Prescriptions Filled as a Result of VitaCare Agr...

Evofem to Present New Research in Gynecological Health at the 2022 American College of Obstetricians and Gynecologists Annual Meeting PR Newswire SAN DIEGO , April 26, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today annou...

Evofem Biosciences to Report First Quarter 2022 Results and Provide Corporate Update on Wednesday, May 4, 2022 PR Newswire -- Conference Call Scheduled for 4:30 p.m. ET – SAN DIEGO , April 25, 2022 /PRNewswire/ -- Evofem Biosciences, In...

Journal of Sexual Medicine Publishes Sexual Satisfaction Data Involving Phexxi® from Evofem's Phase 3 AMPOWER Clinical Trial PR Newswire 88.7% of Women Using Phexxi® (lactic acid, citric acid, and potassium bitartrate Vaginal Gel) Improved or Maintained the...

Evofem Announces Karina Fedasz as Company's New Head of Business Development PR Newswire Fedasz will Focus on Opening New Markets for Evofem's First - and Only – in-Class Contraceptive, Phexxi® (lactic acid, citric acid, and potassium bitartrate) ...

Evofem Biosciences (NASDAQ:EVFM) rallies 18.7% higher premarket after it announced that the Nasdaq Hearings Panel has granted its request to continue its listing on The Nasdaq despite the pending outcome of the stockholder vote on its reverse stock split proposal sche...

Nasdaq Accepts Evofem Plan to Regain Listing Compliance PR Newswire Continued Listing Subject to Receipt of Shareholder Approval for the Reverse Stock Split of Evofem Common Stock before May 4, 2022 , with Compliance by May 20, 2022 SAN DIEGO , ...

Evofem Presents Positive Encore Data in Sexually Transmitted Infections Impacting Women at the 2022 Academy of Managed Care Pharmacy Annual Meeting PR Newswire Phase 2B /3 AMPREVENCE Clinical Trial Concluded with Women Experiencing a 50 Percent Risk Reduction in ...